HEMOSTASIS AND THROMBOGENESIS: PLATELET, ENDOTHELIAL AND CLOTTING FACTOR INTERACTIONS - PowerPoint PPT Presentation

1 / 56
About This Presentation
Title:

HEMOSTASIS AND THROMBOGENESIS: PLATELET, ENDOTHELIAL AND CLOTTING FACTOR INTERACTIONS

Description:

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Extrinsic tenase Intrinsic tenase Prothrombinase HIGHLY SIMPLIFIED ... – PowerPoint PPT presentation

Number of Views:77
Avg rating:3.0/5.0
Slides: 57
Provided by: Arth65
Category:

less

Transcript and Presenter's Notes

Title: HEMOSTASIS AND THROMBOGENESIS: PLATELET, ENDOTHELIAL AND CLOTTING FACTOR INTERACTIONS


1
(No Transcript)
2
HEMODYNAMIC DISORDERS HEMOSTASIS THROMBOGENESIS
PLATELET, ENDOTHELIAL AND CLOTTING FACTOR
INTERACTIONS
  • Arthur S. Schneider, M.D.

3
NORMAL HEMOSTASIS
  • platelets
  • endothelium
  • plasma clotting factors

4
NOTE CLUMPS OF PLATELETS
5
PLATELET FUNCTIONS
  • maintenance of vascular integrity
  • platelet plug formation
  • platelet phospholipid complex expression
  • leads to promotion of coagulation cascade
  • promotion of endothelial repair

6
PLATELET ULTRASTRUCTURE
7
OCS open canalicular system, ?.Galpha
granules, GLYglycogen granules, ECexternal
glycoprotein coat, CM cell membrane, DBdense
bodies, M mitochondria, DTS dense tubular
system, LY lysosomes
8
PLATELET ADHESION TO SUBENDOTHELIUM
9
PLATELET ADHESION TO SUBENDOTHELIUM
10
(No Transcript)
11
PLATELET PLUG FORMATION
12
(No Transcript)
13
(No Transcript)
14
PLATELET INHIBITORS AND PHARMACOLOGIC AGENTS
  • cyclooxygenase inhibitors (aspirin)
  • ADP receptor antagonists (ticlopidine and
    clopidogrel)

15
PLATELET INHIBITORS AND PHARMACOLOGIC AGENTS
  • others
  • phosphodiesterase inhibitors (dipyridamole)
  • increases concentrion of cyclic AMP and cyclic
    GMP --gt potentiation of effect of prostacyclin
  • glycoprotein (GP) IIb/IIIa receptor antagonists
    (eptifibatide, tirofiban and abciximab)

16
ENDOTHELIAL FUNCTIONS
  • metabolic transfers
  • barrier functions
  • synthesis of mediators of interactions between
    endothelium and blood components
  • thromboresistance
  • mediation of vascular repair

17
ENDOTHELIAL THROMBORESISTANCE
  • heparin-like molecules
  • PGI2 and nitric oxide (NO) synthesis
  • plasminogen activation
  • ADP degradation
  • thrombin inactivation
  • thrombomodulin production
  • protein S synthesis

18
HEPARIN-LIKE MOLECULES
  • act at interface of endothelial cells and plasma
  • activate antithrombin III
  • activated AT III cleaves thrombin, factors Xa and
    IXa

19
THROMBOMODULIN
  • endothelial surface protein
  • receptor for thrombin
  • binds thrombin and converts it to an activator of
    protein C
  • activated protein C (APC) cleaves factors Va and
    VIIIa
  • protein S is a cofactor for APC

20
OTHER ACTIONS OF APC
  • contributes to significant reduction of mortality
    in patients with severe sepsis
  • attenuates various deleterious events induced by
    lipopolysaccharide (LPS)
  • cannot be solely explained by its antithrombotic
    activity
  • has associated anti-inflammatory and
    profibrinolytic effects
  • also inhibits tumor necrosis factor-alpha
    (TNF-alpha) production

21
(No Transcript)
22
EVENTS INITIATED BY ENDOTHELIAL DISRUPTION
  • vasoconstriction
  • neurogenic
  • endothelin
  • platelet adhesion and aggregation
  • release of TxA2
  • initiation of coagulation
  • fibrinolysis

23
Classic representation
24
Newer representation
25
(No Transcript)
26
NEWEST REPRESENTATION
  • three distinct phases
  • initiation
  • propagation
  • termination

27
INITIATION
  • chemical or mechanical damage to tissue
  • exposes tissue factor (TF) to the plasma
    circulation
  • induces TF expression by monocytes,and activated
    endothelium

28
INITIATION
  • TF interacts with a small amount of preexistant
    factor VIIa in the plasma, to form extrinsic
    tenase (TF/VIIa/IX/X) on a phospholipid surface
  • rapid inactivation of the extrinsic tenase by
    tissue factor pathway inhibitor (TFPI).
  • extrinsic tenase generates small amounts of
    factors IXa and Xa

29
INITIATION
  • Xa cleaves prothrombin (II) to form small amounts
    of thrombin (IIa)
  • initial small amount of thrombin activates
    cofactor proteins, factors V and VIII to Va and
    VIIIa
  • initial small amount of thrombin also activates
    platelets

30
PROPAGATION
  • cofactor activation (especially VIIIa) ? assembly
    on platelet phospholipid surface of intrinsic
    tenase (VIIIa/IXa,X) ? rapid Xa activation

31
PROPAGATION
  • again on a phospholipid surface, the active
    complex prothrombinase forms (Va/Xa/II/Ca) ?
    accelerated thrombin formation (IIa)
  • thrombin fibrinogen ? fibrin (several steps
    required)
  • removal of fibrinopeptide A and B
  • cross-linking

32
(No Transcript)
33
TERMINATION
  • formation of thrombin/thrombomodulin complex ?
    activated protein C (APC) ? inactivation of Va
    and VIIIa
  • decay of extrinsic tenase through spontaneous
    activity loss and by TFPI
  • inactivation of Xa and thrombin (IIa) by
    antithrombin III

34
HIGHLY SIMPLIFIED VERSION OF NEWEST REPRESENTATION
Extrinsic tenase
Intrinsic tenase
Prothrombinase
35
PROTHROMBIN TIME (PT)
  • measure of extrinsic pathway of coagulation
  • measures Factors VII, X, V, II, and fibrinogen
  • mixture of thromboplastin (tissue factor),
    plasma, calcium ions
  • clot forms in about 12 seconds

36
PARTIAL THROMBOPLASTIN TIME (PTT)
  • often modified to activated partial
    thromboplastin time (APTT)
  • measure of intrinsic pathway of coagulation
  • measures Factors XII, XI, IX, VIII, X, V, II, and
    fibrinogen
  • mixture of phospholipid platelet substitute
    (partial thromboplastin), plasma, calcium ions
  • clot forms in about 25 seconds

37
(No Transcript)
38
(No Transcript)
39
(No Transcript)
40
DISORDERS OF HEMOSTASIS
  • antithrombotic (hemorrhagic) disorders
  • classic hemophilia, Christmas disease, von
    Willebrands disease, disseminated intravascular
    coagulation with consumption coagulopathy, etc.

41
DISORDERS OF HEMOSTASIS
  • prothrombotic (hypercoaguable) states
  • hereditary thrombophilia
  • lupus anticoagulant
  • HIT syndrome (heparin induced thrombocytopenia
    and thrombosis syndrome)
  • disseminated intravascular coagulation (DIC)

42
HEREDITARY THROMBOPHILIA
  • familial
  • most often presents in adolescents or young women
  • venous thrombosis
  • recurrent thromboembolism

43
HEREDITARY THROMBOPHILIA
  • factor V Leiden
  • mutation in factor V (ARG506GLN, 1691G-A, G1691A)
    (arginine to glutamine)
  • causes resistance to activated protein C (APC)
  • prothrombin 20210A transition
  • downstream mutation (prothrombin G20210A)
  • increased prothrombin activity
  • methylene tetrahydrofolate reductase mutation
  • MTHFR C677T

44
HEREDITARY THROMBOPHILIA
  • antithrombin III deficiency
  • protein C deficiency
  • protein S deficiency

45
Amino acid nomenclature





















  • Alanine Ala A
  • Aginine Arg R
  • Asparagine Asn N
  • Aspartic acid Asp D
  • Cysteine Cys C
  • Glutamine Gln Q
  • Glutamic acid Glu E
  • Glycine Gly G
  • Histidine His H
  • Isoleucine Ile I
  • Leucine Leu L
  • Lysine Lys K
  • Methionine Met M
  • Phenylalanine Phe F
  • Proline Pro P
  • Serine Ser S
  • Threonine Thr T
  • Tryptophan Trp W
  • Tyrosine Tyr Y
  • Valine Val V
  • Unspecified Xaa X

46
GENES IMPLICATED IN HEREDITARY THROMBOPHILIA
  • factor V Leiden and other factor V variants
  • prothrombin 20210G-A polymorphism
  • hyperhomocysteinemia and homocystinuria
  • cystathionine synthetase deficiency
  • MTHFR gene (677C-T polymorphism)

47
GENES IMPLICATED IN HEREDITARY THROMBOPHILIA
  • antithrombin 3
  • protein C
  • protein S
  • numerous others
  • histidine-rich glycoprotein
  • plasminogen and plasminogen activator inhibitor
  • fibrinogen-alpha, -beta, and -gamma
  • heparin cofactor II
  • thrombomodulin

48
LUPUS ANTICOAGULANT
  • prolonged partial thromboplastin time
  • antiphospholipid antibodies interfere with PTT
    test
  • increased venous and arterial thrombosis
  • sometimes associated with autoimmune diseases
    such as SLE

49
HIT SYNDROME
  • heparin-induced thrombocytopenia (and
    thrombosis)
  • related to therapy with high molecular weight
    heparin (avoided by using low molecular weight
    heparin
  • caused by antibodies to the complex of heparin
    and platelet factor 4 (PF4)

50
HIT SYNDROME
  • clinical picture is heparin induced
    thrombocytopenia followed by thrombotic
    complications

51
DISSEMINATED INTRAVASCULAR COAGULATION (DIC)
  • obstetric complications
  • retained dead fetus
  • premature separation of placenta (abruptio
    placentae)
  • amniotic fluid embolism
  • gram negative sepsis
  • trauma lung surgery, hemolytic transfusion
    reactions
  • malignancy lung, pancreas, other

52
DISSEMINATED INTRAVASCULAR COAGULATION (DIC)
  • widespread deposition of fibrin in
    microvasculature
  • consumption coagulopathy depletion of platelets
    and coagulation factors
  • factor VIII, factor V, factor II, and fibrinogen

53
DISSEMINATED INTRAVASCULAR THROMBOSIS (DIC)
  • prolongation of prothrombin time (V, II,
    fibrinogen)
  • prolongation of partial thromboplastin time
    (VIII, V, II, fibrinogen)
  • prolongation of thrombin time (fibrinogen)
  • presence of fibrin-fibrinogen degradation (split)
    products (FDP)

54
MICROTHROMBI IN GLOMERULUS IN DIC
55
MICROTHROMBI IN GLOMERULUS IN DIC
56
Thank you for your attention.
Write a Comment
User Comments (0)
About PowerShow.com